Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story

被引：18
作者：
Barosi, Giovanni [1 ]
Gale, Robert Peter [2 ]
机构：
[1] Policlin S Matteo Fdn, Ist Ricovero & Cura Carattere Sci, Gen Med 2, Ctr Study Myelofibrosis, Pavia, Italy
[2] Imperial Coll London, Dept Immunol & Inflammat, Ctr Haematol Res, London, England
来源：
BLOOD ADVANCES | 2022年 / 6卷 / 07期
关键词：
AVAILABLE THERAPY; EFFICACY; SAFETY;
D O I：
10.1182/bloodadvances.2022007230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2331 / 2333
页数：3
相关论文
共 18 条
[1]   Patients' preferences within randomised trials: systematic review and patient level meta-analysis [J].
Adamson, Simon J. ;
Bland, J. Martin ;
Hay, Elaine M. ;
Johnson, Ruth E. ;
Jones, Gareth T. ;
Kitchener, Henry ;
Moffett, Jennifer A. Klaber ;
Macfarlane, Gary J. ;
MacPherson, Hugh ;
McLean, Sionnadh ;
Nelson, Linsey ;
Salisbury, Chris ;
Thomas, Elaine ;
Tilbrook, Helen E. ;
Torgerson, David J. .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 :85-87
[2]   Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? [J].
Barosi, G. ;
Zhang, M-J ;
Gale, R. Peter .
LEUKEMIA, 2014, 28 (11) :2267-2270
[3]   Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis [J].
Barosi, Giovanni ;
Rosti, Vittorio ;
Gale, Robert Peter .
ONCOTARGETS AND THERAPY, 2015, 8 :1091-1102
[4]   Does ruxolitinib prolong the survival of patients with myelofibrosis? [J].
Cervantes, Francisco ;
Pereira, Arturo .
BLOOD, 2017, 129 (07) :832-837
[5]   Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis [J].
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Kiladjian, Jean-Jacques ;
Al-Ali, Haifa Kathrin ;
Sirulnik, Andres ;
Stalbovskaya, Viktoriya ;
McQuitty, Mari ;
Hunter, Deborah S. ;
Levy, Richard S. ;
Passamonti, Francesco ;
Barbui, Tiziano ;
Barosi, Giovanni ;
Harrison, Claire N. ;
Knoops, Laurent ;
Gisslinger, Heinz .
BLOOD, 2013, 122 (25) :4047-4053
[6]   Evolution of the Randomized Clinical Trial in the Era of Precision Oncology [J].
Del Paggio, Joseph C. ;
Berry, John S. ;
Hopman, Wilma M. ;
Eisenhauer, Elizabeth A. ;
Prasad, Vinay ;
Gyawali, Bishal ;
Booth, Christopher M. .
JAMA ONCOLOGY, 2021, 7 (05) :728-734
[7]   Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study [J].
Guglielmelli, Paola ;
Ghirardi, Arianna ;
Carobbio, Alessandra ;
Masciulli, Arianna ;
Maccari, Chiara ;
Mora, Barbara ;
Rumi, Elisa ;
Triguero, Ana ;
Finazzi, Maria Chiara ;
Pettersson, Helna ;
Paoli, Chiara ;
Mannelli, Francesco ;
Vanni, Daniele ;
Rambaldi, Alessandro ;
Passamonti, Francesco ;
Alvarez-Larran, Alberto ;
Andreasson, Bjorn ;
Vannucchi, Alessandro M. ;
Barbui, Tiziano .
BLOOD ADVANCES, 2022, 6 (02) :373-375
[8]   GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations [J].
Guyatt, Gordon H. ;
Oxman, Andrew D. ;
Vist, Gunn E. ;
Kunz, Regina ;
Falck-Ytter, Yngve ;
Alonso-Coello, Pablo ;
Schuenemann, Holger J. .
BRITISH MEDICAL JOURNAL, 2008, 336 (7650) :924-926
[9]   JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].
Harrison, Claire ;
Kiladjian, Jean-Jacques ;
Al-Ali, Haifa Kathrin ;
Gisslinger, Heinz ;
Waltzman, Roger ;
Stalbovskaya, Viktoriya ;
McQuitty, Mari ;
Hunter, Deborah S. ;
Levy, Richard ;
Knoops, Laurent ;
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Barbui, Tiziano ;
Barosi, Giovanni .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798
[10]  
Mart ~i-Carvajal AJ, 2015, COCHRANE DB SYST REV
12